Regional cerebral blood flow in parkinson's disease as an indicator of cognitive impairment

Nuclear Medicine Communications

Volumn 27, Issue 12, 2006, Pages 945-951

  Derejko, Mirosława ^a   Sławek, Jarosław ^b   Wieczorek, Dariusz ^a   Brockhuis, Bogna ^a   Dubaniewicz, Mirosława ^a   Lass, Piotr ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cognitive impairment; Dementia; Parkinson's disease; Regional cerebral blood flow; Single photon emission tomography

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M;

ADULT; AGED; ARTICLE; BRAIN BLOOD FLOW; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PARIETAL LOBE; PARKINSON DISEASE; PSYCHOLOGIC TEST; REGRESSION ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; TEMPORAL CORTEX; TEMPORAL LOBE; THALAMUS;

AGED; AGED, 80 AND OVER; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; CYSTEINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33750682350     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000243370.18883.62     Document Type: Article

References (43)

1. Korczyn AD. Dementia in Parkinson's disease. J Neurol 2001; Suppl 3:1-4.
2. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Midham RHS, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 2000; 54:1596-1602.
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in idiopathic Parkinson's disease: a community-based, prospective study. Neurology 2001; 56:730-736.
4. Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm 1997; 51(suppl):57-82.
5. Hurtig HJ, Trojanowski JO, Galvin J, Ewbank D, Schmidt ML, Lee VM, et al. Aphasynuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 10:1916-1921.
6. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology. Arch Neurol 2002; 59:102-112.
7. Hughes AJ, Daniel SE, Blankson SE, Lees AL. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-148.
8. Sawada H, Udaka F, Kameyama M, Seriu N, Nishinaka K, Shindou K, et al. SPET findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry 1992; 55:960-963.
9. m-HMPAO SPET in Parkinson's disease. Nucl Med Commun 1992; 13:744-748.
10. Defebvre LJP, Leduc V, Duhamel A, Leconffe P, Pasquier F, Lamy-Lhullier C, et al. Technetium HMPAO SPET study in dementia with Lewy bodies, Alzheimer's disease and idiopathic Parkinson's disease. J Nucl Med 1999; 40:956-962.
11. Antonini A, Benti R, Sacilatto G, Meucci N, Canesi M, Gerundini P, Pezzoli G. ECD/SPET perfusion in Parkinson's disease with and without dementia. Mov Disord 2000; 15(suppl 3):219.
12. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999; 1:33-39.
13. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatry Res 1975; 12:189-198.
14. Lezak MD. Neuropsychological assessment. New York: Oxford University Press; 1995.
15. Weidlich S, Lamberti G. DCS - a visual learning and memory test for neuropsychological assessment, 3rd edn. Seattle-USA.: Hogrefe & Huber Publishers; 1998.
16. Saint-Cyr A, Taylor AE, Lang AE. Procedural learning and neostriatal dysfunction in man. Brain 1988; 111:941-959.
17. White RF. Clinical syndromes in adult neuropsychology. Amsterdam: Elsevier; 1992.
18. Pirozzolo FJ, Hansch EC, Mortimer JA, Webster DD, Kuskowski MA. Dementia in Parkinson's disease. A Neuropsychological analysis. Brain Cogn 1982; 1:71-83.
19. Łucki W. Zestaw prób do badania procesów poznawczych u pacjentów z uszkodzeniami (Test Battery for Cognitive Function Assessment in Patients with Brain Damage) Warsaw: Pracowania Testów Psychologicznych PTP, 1995.
20. Austin MP, Ross M, Murray C, O'Carroll RE, Ebmeier KP, Goodwin GM. Cognitive function in major depression. J Affect Disord 1992; 15:21-30.
21. Beck AT. Beck depression inventory. San Antonio, Texas: Psychological Corporation; 1987.
22. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17:427-442.
23. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: MacMillan Healthcare Information; 1987.
24. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson IML, eds. Third symposium on surgery in Parkinson's disease. Edinburgh: Livingstone; 1969, pp. 152-157.
25. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992; 49:1262-1268.
26. 99mTc]-HM-PAO SPECT in Parkinson's disease. J Cereb Blood Flow Metab 1988; 8:101-108.
27. 123I-iodoamphetamine. Dementia 1993; 4:334-341.
28. Kawabata K, Tachibana H, Sugita M. Cerebral blood flow and dementia in Parkinson's disease. J Geriatr Psychiatry Neurol 1991; 4:194-203.
29. Jagust W, Bruce RR, Eileen MM, Eberling JL, Nelson-Abbott RA. Cognitive function and regional cerebral blood flow in Parkinson's disease. Brain 1992; 115:521-537.
30. 99mTc-Bicisate SPECT in asymmetric Parkinson's disease: studies with and without chronic drug therapy. J Cerebral Blood Flow and Metabolism 1994; 14(suppl 1):106-114.
31. 18 F]fluorodopa positron emission tomographic studies. Mov Disord 1990; 5:203-213.
32. Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002; 109:329-339.
33. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord 2003; 18(suppl 6):63-71.
34. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus ceruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson's diseases. Arch Neurol 2003; 3:337-341.
35. Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O'Brien JT. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage 2003; 2:1309-1319.
36. Burn DJ, Rowan EN, Minett T. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 2003; 18:884-889.
37. McKeith IG, Burn D. Spectrum of Parkinson's disease, Parkinson's dementia and Lewy body dementia. Neurol Clin 2000; 18:865-883.
38. Aarsland D, Laake K, Larsen JP. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72:708-712.
39. Brown DF, Risser RC, Bigio EH. Neocortical synapse density and Braak stage in the Lewy body variant of Alzheimer disease: a comparison with classic Alzheimer disease and normal aging. J Neuropathol Exp Neurol 1998; 57:955-960.
40. O'Brien J, Colloby S. Neuromaging. In: O'Brien J, McKeith I, Ames D, Chiu E, eds. Dementia with Lewy bodies and Parkinson's disease. London and New York: Taylor & Francis; 2006, pp. 129-140.
41. Hughes AJ, Daniel SE, Blankson SE, Lees AL. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50:140-148.
42. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neurol Transm 2003; 110:517-536.
43. Schapiro MB, Pietrini P, Grady CL, Ball MJ, DeCarli C, Kumar A, Kaye JA, Haxby JV. Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease. J Neurol Neurosurg Psychiatry 1993; 56:859-864.